HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.

Abstract
Antimicrobial resistance has become one of the greatest threats to public health, with rising resistance to carbapenems being a particular concern due to the lack of effective and safe alternative treatment options. Carbapenem-resistant gram-negative bacteria of clinical relevance include the Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and more recently, Stenotrophomonas maltophilia. Colistin and tigecycline have been used as first-line agents for the treatment of infections caused by these pathogens; however, there are uncertainties regarding their efficacy even when used in combination with other agents. More recently, several new agents with activity against certain carbapenem-resistant pathogens have been approved for clinical use or are reaching late-stage clinical development. They include ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, plazomicin, eravacycline, and cefiderocol. In addition, fosfomycin has been redeveloped in a new intravenous formulation. Data regarding the clinical efficacy of these new agents specific to infections caused by carbapenem-resistant pathogens are slowly emerging and appear to generally favor newer agents over previous best available therapy. As more treatment options become widely available for carbapenem-resistant gram-negative infections, the role of antimicrobial stewardship will become crucial in ensuring appropriate and rationale use of these new agents.
AuthorsYohei Doi
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 69 Issue Suppl 7 Pg. S565-S575 (11 13 2019) ISSN: 1537-6591 [Electronic] United States
PMID31724043 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Chemical References
  • Anti-Bacterial Agents
  • Carbapenems
Topics
  • Anti-Bacterial Agents (therapeutic use)
  • Antimicrobial Stewardship
  • Carbapenems (therapeutic use)
  • Clinical Trials as Topic
  • Drug Resistance, Bacterial
  • Forecasting
  • Gram-Negative Bacterial Infections (drug therapy)
  • Humans
  • Public Health

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: